Redhill Biopharma (NASDAQ:RDHL – Get Free Report) is expected to be releasing its H1 2026 resultson Thursday, August 20th. Analysts expect the company to post earnings of ($435.00) per share and revenue of $22.7030 million for the quarter. Investors may review the information on the company’s upcoming H1 2026 earning report for the latest details on the call scheduled for Thursday, August 27, 2026 at 12:30 PM ET.
Redhill Biopharma Stock Performance
Shares of RDHL stock opened at $0.58 on Tuesday. Redhill Biopharma has a one year low of $0.58 and a one year high of $2.79. The company has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.87. The firm has a market capitalization of $3.56 million, a price-to-earnings ratio of 0.00 and a beta of 5.00.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a report on Monday, August 3rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Redhill Biopharma presently has a consensus rating of “Sell”.
Redhill Biopharma Company Profile
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.
RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.
Further Reading
- Five stocks we like better than Redhill Biopharma
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
